Jazz Pharmaceuticals Strikes Major Collaboration with AbCellera for Next-Generation Multispecific Antibodies
Jazz Pharmaceuticals and AbCellera enter a collaboration worth up to $876 million to develop next-generation T-cell engaging multispecific antibodies for GI cancers and solid tumors.